CTI BioPharma to Report Third Quarter 2022 Financial Results on November 7, 2022

Rhea-AI Summary

CTI BioPharma Corp. (NASDAQ: CTIC) will release its third quarter 2022 financial results on November 7, 2022, after U.S. market close. A conference call will follow at 4:30 p.m. ET to discuss the results and provide a corporate update. The company focuses on targeted therapies for blood-related cancers and has one FDA-approved product, VONJO (pacritinib), for treating certain types of myelofibrosis. Continued FDA approval may depend on further clinical validation.

Positive

• CTI BioPharma has one FDA-approved product, VONJO, indicating successful drug development.
• The upcoming Q3 2022 financial results may provide insight into financial health and market performance.

Negative

• Continued FDA approval for VONJO is contingent upon additional clinical trial confirmation.

SEATTLE, Oct. 27, 2022 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2022 financial results on Monday, November 7, 2022, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).

To participate via telephone, please register in advance using this link: https://register.vevent.com/register/BI1dc7f17da2ae4ce8ba0e490c169604ac. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including a dial-in number and a unique registrant ID. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.

About CTI BioPharma Corp.
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product, VONJO^® (pacritinib), a JAK2 and IRAK1 inhibitor, that spares JAK1. VONJO is approved for the treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.

VONJO^® is a registered trademark of CTI BioPharma Corp.

CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-report-third-quarter-2022-financial-results-on-november-7-2022-301661375.html

SOURCE CTI BioPharma Corp.

FAQ

When will CTI BioPharma report its Q3 2022 financial results?

CTI BioPharma will report its Q3 2022 financial results on November 7, 2022.

What time will the conference call for CTI BioPharma's Q3 results take place?

The conference call will take place at 4:30 p.m. ET.

What product does CTI BioPharma have approved by the FDA?

CTI BioPharma has FDA approval for VONJO (pacritinib) for treating myelofibrosis.

What is the indication for the FDA approval of VONJO?

VONJO is approved for adults with intermediate- or high-risk myelofibrosis with low platelet counts.

What is the Phase 3 PACIFICA study related to CTI BioPharma?

The PACIFICA study is a confirmatory trial for VONJO in patients with myelofibrosis and severe thrombocytopenia.